Clinical Trials Logo

Cough clinical trials

View clinical trials related to Cough.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06246565 Not yet recruiting - Cough Clinical Trials

A Study of HS-10383 in Chinese Adult Subjects With Refractory or Unexplained Chronic Cough (RUCC)

Start date: March 1, 2024
Phase: Phase 2
Study type: Interventional

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-designed phase 2 clinical trial to evaluate the efficacy, safety and pharmacokinetic (PK) characteristics of HS-10383 in Chinese adult subjects with refractory or unexplained chronic cough (RUCC).

NCT ID: NCT06246370 Not yet recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

An Investigation of the Cervical Region Biomechanics in Patients With Chronic Obstructive Pulmonary Disease

Start date: February 20, 2024
Phase:
Study type: Observational

The aim of this study is to investigate cervical region biomechanics, muscle performance and respiratory muscle strength in patients with Chronic Obstructive Pulmonary Disease (COPD) compared to healthy subjects.

NCT ID: NCT06213363 Not yet recruiting - Clinical trials for Refractory Chronic Cough

A Phase Ib/II Clinical Study in Patients With Refractory Chronic Cough

Start date: February 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a multicenter, randomized, double-blind, placebo-controlled Phase Ib/II clinical trial to evaluate the effectiveness, safety, tolerability and pharmacokinetics (PK) of TCR1672 Tablets in patients with refractory chronic cough.

NCT ID: NCT05983471 Not yet recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Efficacy and Safety of ME-015 (Suplatast Tosilate) in Cough Related to Idiopathic Pulmonary Fibrosis (COSMIC-IPF)

COSMIC-IPF
Start date: November 2023
Phase: Phase 2
Study type: Interventional

Orally administered ME-015 (Suplatast Tosilate) has been available on the market as a prescription drug for allergy-related conditions in Japan since 1995 with a very good safety and tolerability profile. There is preclinical and exploratory clinical evidence suggesting that ME-015 may be effective in treating cough caused by idiopathic pulmonary fibrosis (IPF-cough). 80% of patients with idiopathic pulmonary fibrosis (IPF) are affected by a devastating dry cough that is often not responsive to standard cough treatments and causes significant psychological and physiological suffering as well as reduced quality of life. As of July 2023, there is no approved treatment for the indication of IPF-cough. There is an enormous unmet clinical need for an effective, safe and well-tolerated oral treatment. The COSMIC-IPF Phase 2 trial is the first clinical trial assessing ME-015 for the treatment of IPF-cough and aims to generate clinical proof-of-concept results regarding the safety and efficacy of ME-015 in this condition.

NCT ID: NCT05888350 Not yet recruiting - Cough Clinical Trials

Biomarkers for Predicting the Response to Inhaled Corticosteroid in Patients With Chronic Cough.

CC-ICS
Start date: July 30, 2023
Phase: N/A
Study type: Interventional

To investigate the value of blood eosinophils, FeNO and total IgE in predicting the response to inhaled corticosteroid in patients with chronic cough.

NCT ID: NCT05713019 Not yet recruiting - Cough Clinical Trials

ATP and P2X3 Receptor in Chronic Cough

Start date: February 28, 2023
Phase: N/A
Study type: Interventional

This is a laboratory-based study that will be performed at the Clinical Research Centre at the Royal Brompton Hospital,London. The objectives are: 1. Determine whether adenosine triphosphate (ATP) is present or released in airways of idiopathic chronic cough patients 2. Determine whether there is an increase in cough sensitivity and laryngeal sensitivity to exogenous ATP 3. Examine the effects of exogenous ATP on the inflammatory response in the upper and lower airways. The participants will be: (i) Healthy subjects: non-smoker (8 subjects) and (ii) Chronic cough subjects attending Chronic Cough clinic (12 subjects). Each will be involved in: Study 1. Following recruitment, subjects will attend for a fiberoptic bronchoscopy. Study 2: Subjects will take part in a study of the effect of inhaling nebulized ATP. Subjects will be studied on 2 days separated by at least 5 days. On each day, after measurements of lung function, FeNO and cough questionnaires, the subject will inhale either saline or ATP solution from a nebulizer, following which laryngeal hypersensitivity, capsaicin cough challenge and sputum induction will be performed. Results will be expressed as mean ± standard error of the mean (SEM). Study data will be analysed by the Investigators at the completion of the study. Planned analyses will be done by comparing chronic cough patients to the healthy controls. The Spearman rank-correlation test will be used to determine correlations.

NCT ID: NCT05532449 Not yet recruiting - Clinical trials for Sufentanil-induced Cough

Dezoxide Suppresses Sufentanil-induced Cough

Start date: September 12, 2022
Phase: N/A
Study type: Interventional

Dizocine (0.03 mg/kg) or saline followed by sufentanil 0.4ug/kg was administered, and induction was completed with 3 min of observation. Heart rate and mean arterial pressure (MAP) were recorded before induction of anesthesia, before and 1 min after intubation, and side effects during induction, such as vomiting, hypoxemia (SpO2 <90%), or other expected effects. The number of coughs was recorded in both groups, and the severity of cough was defined as follows: mild, 1-2 coughs; moderate, 3-4 coughs; severe, 5 or more coughs.

NCT ID: NCT05472350 Not yet recruiting - Cough Clinical Trials

Efficacy and Safety of Perioperative Use of Breztri Aerosphere to Relieve Cough After Lobectomy

Start date: August 1, 2022
Phase: N/A
Study type: Interventional

Cough after lobectomy is common. The prevention and treatment of cough after lobectomy is not standardized. Breztri Aerosphere is often used to relieve cough. Therefore, we conduct a single center placebo-controlled study to evaluate the efficacy and safety of perioperative use of Breztri Aerosphere in relieving cough after lobectomy.

NCT ID: NCT05317156 Not yet recruiting - Dysphagia Clinical Trials

The Effect of Cold Vapor on Intubation-Related Symptoms and Comfort in the Early Postoperative Period

Start date: April 18, 2022
Phase: N/A
Study type: Interventional

Endotracheal Intubation (EI) is performed in order to monitor the effectiveness of anesthesia and to control the patient's breathing during the surgery under general anesthesia. In EI, which is an invasive procedure, damage to the larynx and trachea may occur during the placement of the endotracheal tube or due to long-term use. Complications such as postintubation ulcer, laryngeal nerve paresis, arytenoid dislocation may develop in the early period due to EI, and patients may have complaints such as sore throat, swallowing problems, hoarseness, and cough in the postoperative period. This affects the comfort of the patients in the postoperative period. For this reason, it is important to prevent intubation-related symptoms of patients who will undergo surgical intervention before they occur.

NCT ID: NCT05265871 Not yet recruiting - Clinical trials for Refractory Chronic Cough

ATP Level and Cough Sensitivity to ATP in Subjects With Refractory Chronic Cough

Start date: April 15, 2022
Phase:
Study type: Observational

This is a prospective case - control study to investigate ATP level in induced sputum and cough sensitivity to ATP in subjects with refractory chronic cough. 60 refractory chronic cough and 30 matched healthy controls were recruited. Medical history records, cough severity assessment, induced sputum for ATP measurement, ATP evoked cough and capsaicin evoked cough were completed. The difference of sputum ATP level between patients and control and the correlation between sputum ATP level and cough sensitivity to ATP were analyzed.